These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 29913272)
21. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Koldehoff M; Elmaagacli AH Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661 [TBL] [Abstract][Full Text] [Related]
22. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662 [TBL] [Abstract][Full Text] [Related]
23. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562]. Wang W; DU Y; Lin GQ; Li NN; Sun BZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411 [TBL] [Abstract][Full Text] [Related]
24. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH Clin Exp Med; 2007 Jun; 7(2):47-55. PubMed ID: 17609876 [TBL] [Abstract][Full Text] [Related]
26. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research. Peng C; Li S Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093 [TBL] [Abstract][Full Text] [Related]
27. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140 [TBL] [Abstract][Full Text] [Related]
28. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA. Li MJ; McMahon R; Snyder DS; Yee JK; Rossi JJ Oligonucleotides; 2003; 13(5):401-9. PubMed ID: 15000831 [TBL] [Abstract][Full Text] [Related]
29. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
30. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia]. Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325 [TBL] [Abstract][Full Text] [Related]
31. Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates. Shinkai Y; Kashihara S; Minematsu G; Fujii H; Naemura M; Kotake Y; Morita Y; Ohnuki K; Fokina AA; Stetsenko DA; Filichev VV; Fujii M Nucleic Acid Ther; 2017 Jun; 27(3):168-175. PubMed ID: 28355131 [TBL] [Abstract][Full Text] [Related]
32. Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy. Ansari AS; K C R; Jiang X; Uludaǧ H J Biomed Mater Res A; 2021 Nov; 109(11):2306-2321. PubMed ID: 33964112 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Zhu X; Li Y; Luo X; Fei J Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069 [TBL] [Abstract][Full Text] [Related]
35. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia. Wang W; Du Y; Li NN; Lv FF; Lin GQ Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701 [TBL] [Abstract][Full Text] [Related]
36. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Li QF; Huang WR; Duan HF; Wang H; Wu CT; Wang LS Oncogene; 2007 Dec; 26(57):7904-8. PubMed ID: 17599053 [TBL] [Abstract][Full Text] [Related]
37. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia. Vysochinskaya V; Dovbysh O; Gorshkov A; Brodskaia A; Dubina M; Vasin A; Zabrodskaya Y Biomolecules; 2024 May; 14(6):. PubMed ID: 38927048 [TBL] [Abstract][Full Text] [Related]
38. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145 [TBL] [Abstract][Full Text] [Related]
39. A novel fusion circular RNA F-circBA1 derived from the Tan Y; Huang Z; Wang X; Dai H; Jiang G; Feng W Bioengineered; 2021 Dec; 12(1):4816-4827. PubMed ID: 34346842 [TBL] [Abstract][Full Text] [Related]
40. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo]. Zhu YF; Wang YZ; Meng FY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]